Denali Advisors’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Denali Advisors’s Portfolio PRVB Stock Details PRVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-4,300	Closed	-$104K	–	532
2023 Q1	$104K	Hold	4,300	–	–	0.04%	177
2022 Q4	$45.5K	Sell	4,300 -2,700	-39%	-$21.8K	0.02%	237
2022 Q3	$32K	Hold	7,000	–	–	0.02%	254
2022 Q2	$28K	Hold	7,000	–	–	0.01%	273
2022 Q1	$51K	Hold	7,000	–	–	0.02%	239
2021 Q4	$39K	Buy	+7,000	New	+$44.5K	0.01%	274

Other funds holding PRVB

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Denali Advisors's PRVB Position: Q2 2023 in Review

Denali Advisors sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 4,300 shares — an estimated $104K sold.

Denali Advisors first reported a position in PRVB in Q4 2021 and held it in 6 quarters. The position peaked at $104K in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.

Denali Advisors reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Denali Advisors sold 4,300 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $104K.
Denali Advisors first reported a position in Provention Bio, Inc. Common Stock in Q4 2021 and held it in 6 quarters.
Denali Advisors's Provention Bio, Inc. Common Stock position peaked at $104K in Q1 2023.
1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.

Based on Denali Advisors's 13F filing for Q2 2023, filed 18 Jul 2023.